CERS catalyst calendar

CERUS CORP

Upcoming catalysts
3
Cash runway
17.7 months
Cash & investments
$18M
Phase 3 programs
3

CERUS CORP is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Surgical & Medical Instruments & Apparatus.

The next scheduled catalyst is Next quarterly earnings (projected) on December 11, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 17.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 14 concluded trials, 79% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 11, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 Trial Milestone Phase 2
September 30, 2030 Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs Trial Milestone Phase 2

Track CERS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open CERS in the tracker

Recent history

DateEventTypePhase
July 30, 2026 Quarterly results filed (8-K) Earnings —
July 10, 2026 8-K filed: Leadership change Corporate —
June 8, 2026 8-K filed: Material agreement Corporate —
June 3, 2026 8-K filed: Leadership change Corporate —
April 30, 2026 Quarterly results filed (8-K) Earnings —
April 29, 2026 INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections Trial Milestone Phase 3
April 21, 2026 8-K filed: Leadership change Corporate —
March 16, 2026 8-K filed: Leadership change Corporate —
March 2, 2026 Quarterly results filed (8-K) Earnings —
January 23, 2026 8-K filed: Leadership change Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
November 6, 2025 Quarterly results filed (8-K) Earnings —
August 5, 2025 Quarterly results filed (8-K) Earnings —
June 23, 2025 8-K filed: Leadership change Corporate —
June 9, 2025 8-K filed: Leadership change Corporate —
June 2, 2025 A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator. Trial Milestone Phase 2
May 1, 2025 Quarterly results filed (8-K) Earnings —
December 4, 2023 Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients Trial Milestone Phase 3
April 16, 2021 In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days Trial Milestone Phase 2
December 15, 2020 A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease Trial Milestone Phase 1
December 21, 2017 Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.